टैम्सुलोसिन के इंटरैक्शन

• Should not be used in combination with other alpha adrenergic blocking agents ( 5.2 , 7.2 , 12.3 ) (टैम्सुलोसिन लेबल, चेतावनियां और सावधानियां)

• Should not be used in combination with strong inhibitors of CYP3A4. (टैम्सुलोसिन लेबल, चेतावनियां और सावधानियां)

• Should not be used in combination with strong inhibitors of CYP3A4. (टैम्सुलोसिन लेबल, चेतावनियां और सावधानियां)

• Should not be used in combination with strong inhibitors of CYP3A4. (टैम्सुलोसिन लेबल, चेतावनियां और सावधानियां)

• Should not be used in combination with strong inhibitors of CYP3A4. (टैम्सुलोसिन लेबल, चेतावनियां और सावधानियां)

Avoid coadministration of FANAPT with alpha-adrenergic blocking agents and adjust medications that affect blood pressure as needed [see Warnings and Precautions (5.7) ] . (इलोपेरिडोन लेबल, दवाओं के इंटरैक्शन)

• Should not be used in combination with strong inhibitors of CYP3A4. (टैम्सुलोसिन लेबल, चेतावनियां और सावधानियां)

• Should not be used in combination with strong inhibitors of CYP3A4. (टैम्सुलोसिन लेबल, चेतावनियां और सावधानियां)

• Should not be used in combination with strong inhibitors of CYP3A4. (टैम्सुलोसिन लेबल, चेतावनियां और सावधानियां)

• Should not be used in combination with strong inhibitors of CYP3A4. (टैम्सुलोसिन लेबल, चेतावनियां और सावधानियां)

• Should not be used in combination with strong inhibitors of CYP3A4. (टैम्सुलोसिन लेबल, चेतावनियां और सावधानियां)

• Should not be used in combination with strong inhibitors of CYP3A4. (टैम्सुलोसिन लेबल, चेतावनियां और सावधानियां)

• Should not be used in combination with strong inhibitors of CYP3A4. (टैम्सुलोसिन लेबल, चेतावनियां और सावधानियां)

• Should not be used in combination with strong inhibitors of CYP3A4. (टैम्सुलोसिन लेबल, चेतावनियां और सावधानियां)

If a patient reports a serious or life-threatening sulfa allergy, caution is warranted when administering tamsulosin hydrochloride capsules. (टैम्सुलोसिन लेबल, चेतावनियां और सावधानियां)

• Should not be used in combination with other alpha adrenergic blocking agents ( 5.2 , 7.2 , 12.3 ) (टैम्सुलोसिन लेबल, चेतावनियां और सावधानियां)

• Should not be used in combination with strong inhibitors of CYP3A4. (टैम्सुलोसिन लेबल, चेतावनियां और सावधानियां)

• Should not be used in combination with strong inhibitors of CYP3A4. (टैम्सुलोसिन लेबल, चेतावनियां और सावधानियां)

If a patient reports a serious or life-threatening sulfa allergy, caution is warranted when administering tamsulosin hydrochloride capsules. (टैम्सुलोसिन लेबल, चेतावनियां और सावधानियां)

• Should not be used in combination with strong inhibitors of CYP3A4. (टैम्सुलोसिन लेबल, चेतावनियां और सावधानियां)

• Should not be used in combination with other alpha adrenergic blocking agents ( 5.2 , 7.2 , 12.3 ) (टैम्सुलोसिन लेबल, चेतावनियां और सावधानियां)

CIALIS is not recommended in combination with alpha-blockers for the treatment of BPH because efficacy of the combination has not been adequately studied and because of the risk of blood pressure lowering. (टैडालाफिल लेबल, चेतावनियां और सावधानियां)

If a patient reports a serious or life-threatening sulfa allergy, caution is warranted when administering tamsulosin hydrochloride capsules. (टैम्सुलोसिन लेबल, चेतावनियां और सावधानियां)

• Should not be used in combination with strong inhibitors of CYP3A4. (टैम्सुलोसिन लेबल, चेतावनियां और सावधानियां)

• Should not be used in combination with strong inhibitors of CYP3A4. (टैम्सुलोसिन लेबल, चेतावनियां और सावधानियां)

• Should not be used in combination with strong inhibitors of CYP3A4. (टैम्सुलोसिन लेबल, चेतावनियां और सावधानियां)

• Should not be used in combination with other alpha adrenergic blocking agents ( 5.2 , 7.2 , 12.3 ) (टैम्सुलोसिन लेबल, चेतावनियां और सावधानियां)

If a patient reports a serious or life-threatening sulfa allergy, caution is warranted when administering tamsulosin hydrochloride capsules. (टैम्सुलोसिन लेबल, चेतावनियां और सावधानियां)

If a patient reports a serious or life-threatening sulfa allergy, caution is warranted when administering tamsulosin hydrochloride capsules. (टैम्सुलोसिन लेबल, चेतावनियां और सावधानियां)

• Should not be used in combination with other alpha adrenergic blocking agents ( 5.2 , 7.2 , 12.3 ) (टैम्सुलोसिन लेबल, चेतावनियां और सावधानियां)

• Should not be used in combination with strong inhibitors of CYP3A4. (टैम्सुलोसिन लेबल, चेतावनियां और सावधानियां)

• Should not be used in combination with strong inhibitors of CYP3A4. (टैम्सुलोसिन लेबल, चेतावनियां और सावधानियां)

• Should not be used in combination with strong inhibitors of CYP3A4. (टैम्सुलोसिन लेबल, चेतावनियां और सावधानियां)

• Should not be used in combination with strong inhibitors of CYP3A4. (टैम्सुलोसिन लेबल, चेतावनियां और सावधानियां)

• Should not be used in combination with strong inhibitors of CYP3A4. (टैम्सुलोसिन लेबल, चेतावनियां और सावधानियां)

• Should not be used in combination with strong inhibitors of CYP3A4. (टैम्सुलोसिन लेबल, चेतावनियां और सावधानियां)

• Should not be used in combination with other alpha adrenergic blocking agents ( 5.2 , 7.2 , 12.3 ) (टैम्सुलोसिन लेबल, चेतावनियां और सावधानियां)

• Should not be used in combination with other alpha adrenergic blocking agents ( 5.2 , 7.2 , 12.3 ) (टैम्सुलोसिन लेबल, चेतावनियां और सावधानियां)

• Should not be used in combination with other alpha adrenergic blocking agents ( 5.2 , 7.2 , 12.3 ) (टैम्सुलोसिन लेबल, चेतावनियां और सावधानियां)

• Should not be used in combination with strong inhibitors of CYP3A4. (टैम्सुलोसिन लेबल, चेतावनियां और सावधानियां)

• Should not be used in combination with strong inhibitors of CYP3A4. (टैम्सुलोसिन लेबल, चेतावनियां और सावधानियां)

• Should not be used in combination with strong inhibitors of CYP3A4. (टैम्सुलोसिन लेबल, चेतावनियां और सावधानियां)

If a patient reports a serious or life-threatening sulfa allergy, caution is warranted when administering tamsulosin hydrochloride capsules. (टैम्सुलोसिन लेबल, चेतावनियां और सावधानियां)

• Should not be used in combination with strong inhibitors of CYP3A4. (टैम्सुलोसिन लेबल, चेतावनियां और सावधानियां)

• Should not be used in combination with strong inhibitors of CYP3A4. (टैम्सुलोसिन लेबल, चेतावनियां और सावधानियां)

If a patient reports a serious or life-threatening sulfa allergy, caution is warranted when administering tamsulosin hydrochloride capsules. (टैम्सुलोसिन लेबल, चेतावनियां और सावधानियां)

• Should not be used in combination with strong inhibitors of CYP3A4. (टैम्सुलोसिन लेबल, चेतावनियां और सावधानियां)

• Should not be used in combination with strong inhibitors of CYP3A4. (टैम्सुलोसिन लेबल, चेतावनियां और सावधानियां)

• Should not be used in combination with strong inhibitors of CYP3A4. (टैम्सुलोसिन लेबल, चेतावनियां और सावधानियां)

• Should not be used in combination with other alpha adrenergic blocking agents ( 5.2 , 7.2 , 12.3 ) (टैम्सुलोसिन लेबल, चेतावनियां और सावधानियां)

• Should not be used in combination with strong inhibitors of CYP3A4. (टैम्सुलोसिन लेबल, चेतावनियां और सावधानियां)

• Should not be used in combination with strong inhibitors of CYP3A4. (टैम्सुलोसिन लेबल, चेतावनियां और सावधानियां)

• Should not be used in combination with strong inhibitors of CYP3A4. (टैम्सुलोसिन लेबल, चेतावनियां और सावधानियां)

If a patient reports a serious or life-threatening sulfa allergy, caution is warranted when administering tamsulosin hydrochloride capsules. (टैम्सुलोसिन लेबल, चेतावनियां और सावधानियां)

If a patient reports a serious or life-threatening sulfa allergy, caution is warranted when administering tamsulosin hydrochloride capsules. (टैम्सुलोसिन लेबल, चेतावनियां और सावधानियां)

If a patient reports a serious or life-threatening sulfa allergy, caution is warranted when administering tamsulosin hydrochloride capsules. (टैम्सुलोसिन लेबल, चेतावनियां और सावधानियां)

• Should not be used in combination with strong inhibitors of CYP3A4. (टैम्सुलोसिन लेबल, चेतावनियां और सावधानियां)

Tamsulosin hydrochloride capsules should be used with caution in combination with cimetidine, particularly at a dose higher than 0.4 mg (e.g., 0.8 mg) [see Drug Interactions ( 7.1 ) and Clinical Pharmacology ( 12.3 )] Tamsulosin hydrochloride capsules should not be used in combination with other alpha adrenergic blocking agents [see Drug Interactions ( 7.2 )… (टैम्सुलोसिन लेबल, चेतावनियां और सावधानियां)

• Should not be used in combination with other alpha adrenergic blocking agents ( 5.2 , 7.2 , 12.3 ) (टैम्सुलोसिन लेबल, चेतावनियां और सावधानियां)

If a patient reports a serious or life-threatening sulfa allergy, caution is warranted when administering tamsulosin hydrochloride capsules. (टैम्सुलोसिन लेबल, चेतावनियां और सावधानियां)

• Should not be used in combination with strong inhibitors of CYP3A4. (टैम्सुलोसिन लेबल, चेतावनियां और सावधानियां)

• Should not be used in combination with strong inhibitors of CYP3A4. (टैम्सुलोसिन लेबल, चेतावनियां और सावधानियां)

Nifedipine, Atenolol, Enalapril Dosage adjustments are not necessary when tamsulosin hydrochloride capsules are administered concomitantly with nifedipine, atenolol, or enalapril [see clinical pharmacology ( 12.3 )] . (टैम्सुलोसिन लेबल, दवाओं के इंटरैक्शन)

Nifedipine, Atenolol, Enalapril Dosage adjustments are not necessary when tamsulosin hydrochloride capsules are administered concomitantly with nifedipine, atenolol, or enalapril [see clinical pharmacology ( 12.3 )] . (टैम्सुलोसिन लेबल, दवाओं के इंटरैक्शन)

Nifedipine, Atenolol, Enalapril Dosage adjustments are not necessary when tamsulosin hydrochloride capsules are administered concomitantly with nifedipine, atenolol, or enalapril [see clinical pharmacology ( 12.3 )] . (टैम्सुलोसिन लेबल, दवाओं के इंटरैक्शन)

Nifedipine, Atenolol, Enalapril Dosage adjustments are not necessary when tamsulosin hydrochloride capsules are administered concomitantly with nifedipine, atenolol, or enalapril [see clinical pharmacology ( 12.3 )] . (टैम्सुलोसिन लेबल, दवाओं के इंटरैक्शन)

Use with caution in combination with moderate inhibitors of CYP3A4, with strong or moderate inhibitors of CYP2D6, in patients known to be CYP2D6 poor metabolizers, or in combination with other cytochrome P450 inhibitors. (टैम्सुलोसिन लेबल, चेतावनियां और सावधानियां)

Digoxin and Theophylline Dosage adjustments are not necessary when a tamsulosin hydrochloride capsule is administered concomitantly with digoxin or theophylline [see Clinical Pharmacology ( 12.3 )] . (टैम्सुलोसिन लेबल, दवाओं के इंटरैक्शन)

Digoxin and Theophylline Dosage adjustments are not necessary when a tamsulosin hydrochloride capsule is administered concomitantly with digoxin or theophylline [see Clinical Pharmacology ( 12.3 )] . (टैम्सुलोसिन लेबल, दवाओं के इंटरैक्शन)

Digoxin and Theophylline Dosage adjustments are not necessary when a tamsulosin hydrochloride capsule is administered concomitantly with digoxin or theophylline [see Clinical Pharmacology ( 12.3 )] . (टैम्सुलोसिन लेबल, दवाओं के इंटरैक्शन)

Caution is advised when alpha adrenergic blocking agents including tamsulosin hydrochloride are coadministered with PDE5 inhibitors. (टैम्सुलोसिन लेबल, चेतावनियां और सावधानियां)

Digoxin and Theophylline Dosage adjustments are not necessary when a tamsulosin hydrochloride capsule is administered concomitantly with digoxin or theophylline [see Clinical Pharmacology ( 12.3 )] . (टैम्सुलोसिन लेबल, दवाओं के इंटरैक्शन)

Use with caution in combination with moderate inhibitors of CYP3A4, with strong or moderate inhibitors of CYP2D6, in patients known to be CYP2D6 poor metabolizers, or in combination with other cytochrome P450 inhibitors. (टैम्सुलोसिन लेबल, चेतावनियां और सावधानियां)

Use with caution in combination with moderate inhibitors of CYP3A4, with strong or moderate inhibitors of CYP2D6, in patients known to be CYP2D6 poor metabolizers, or in combination with other cytochrome P450 inhibitors. (टैम्सुलोसिन लेबल, चेतावनियां और सावधानियां)

Use with caution in combination with moderate inhibitors of CYP3A4, with strong or moderate inhibitors of CYP2D6, in patients known to be CYP2D6 poor metabolizers, or in combination with other cytochrome P450 inhibitors. (टैम्सुलोसिन लेबल, चेतावनियां और सावधानियां)

Use with caution in combination with moderate inhibitors of CYP3A4, with strong or moderate inhibitors of CYP2D6, in patients known to be CYP2D6 poor metabolizers, or in combination with other cytochrome P450 inhibitors. (टैम्सुलोसिन लेबल, चेतावनियां और सावधानियां)

Use with caution in combination with moderate inhibitors of CYP3A4, with strong or moderate inhibitors of CYP2D6, in patients known to be CYP2D6 poor metabolizers, or in combination with other cytochrome P450 inhibitors. (टैम्सुलोसिन लेबल, चेतावनियां और सावधानियां)

Digoxin and Theophylline Dosage adjustments are not necessary when a tamsulosin hydrochloride capsule is administered concomitantly with digoxin or theophylline [see Clinical Pharmacology ( 12.3 )] . (टैम्सुलोसिन लेबल, दवाओं के इंटरैक्शन)

Use with caution in combination with moderate inhibitors of CYP3A4, with strong or moderate inhibitors of CYP2D6, in patients known to be CYP2D6 poor metabolizers, or in combination with other cytochrome P450 inhibitors. (टैम्सुलोसिन लेबल, चेतावनियां और सावधानियां)

Use with caution in combination with moderate inhibitors of CYP3A4, with strong or moderate inhibitors of CYP2D6, in patients known to be CYP2D6 poor metabolizers, or in combination with other cytochrome P450 inhibitors. (टैम्सुलोसिन लेबल, चेतावनियां और सावधानियां)

Use with caution in combination with moderate inhibitors of CYP3A4, with strong or moderate inhibitors of CYP2D6, in patients known to be CYP2D6 poor metabolizers, or in combination with other cytochrome P450 inhibitors. (टैम्सुलोसिन लेबल, चेतावनियां और सावधानियां)

Digoxin and Theophylline Dosage adjustments are not necessary when a tamsulosin hydrochloride capsule is administered concomitantly with digoxin or theophylline [see Clinical Pharmacology ( 12.3 )] . (टैम्सुलोसिन लेबल, दवाओं के इंटरैक्शन)

Use with caution in combination with moderate inhibitors of CYP3A4, with strong or moderate inhibitors of CYP2D6, in patients known to be CYP2D6 poor metabolizers, or in combination with other cytochrome P450 inhibitors. (टैम्सुलोसिन लेबल, चेतावनियां और सावधानियां)

Nifedipine, Atenolol, Enalapril Dosage adjustments are not necessary when tamsulosin hydrochloride capsules are administered concomitantly with nifedipine, atenolol, or enalapril [see clinical pharmacology ( 12.3 )] . (टैम्सुलोसिन लेबल, दवाओं के इंटरैक्शन)

Use with caution in combination with moderate inhibitors of CYP3A4, with strong or moderate inhibitors of CYP2D6, in patients known to be CYP2D6 poor metabolizers, or in combination with other cytochrome P450 inhibitors. (टैम्सुलोसिन लेबल, चेतावनियां और सावधानियां)

Digoxin and Theophylline Dosage adjustments are not necessary when a tamsulosin hydrochloride capsule is administered concomitantly with digoxin or theophylline [see Clinical Pharmacology ( 12.3 )] . (टैम्सुलोसिन लेबल, दवाओं के इंटरैक्शन)

Use with caution in combination with moderate inhibitors of CYP3A4, with strong or moderate inhibitors of CYP2D6, in patients known to be CYP2D6 poor metabolizers, or in combination with other cytochrome P450 inhibitors. (टैम्सुलोसिन लेबल, चेतावनियां और सावधानियां)

Use with caution in combination with moderate inhibitors of CYP3A4, with strong or moderate inhibitors of CYP2D6, in patients known to be CYP2D6 poor metabolizers, or in combination with other cytochrome P450 inhibitors. (टैम्सुलोसिन लेबल, चेतावनियां और सावधानियां)

Alpha Blockers: Co-administration of beta-blockers with alpha-blocker (e.g., prazosin) has been associated with prolongation of first dose hypotension and syncope. (प्रोप्रानोलोल लेबल, दवाओं के इंटरैक्शन)

Digoxin and Theophylline Dosage adjustments are not necessary when a tamsulosin hydrochloride capsule is administered concomitantly with digoxin or theophylline [see Clinical Pharmacology ( 12.3 )] . (टैम्सुलोसिन लेबल, दवाओं के इंटरैक्शन)

While furosemide produced an 11% to 12% reduction in tamsulosin hydrochloride C max and AUC, these changes are expected to be clinically insignificant and do not require adjustment of the tamsulosin hydrochloride capsules dosage [see Clinical Pharmacology ( 12.3 )] . (टैम्सुलोसिन लेबल, दवाओं के इंटरैक्शन)

Use with caution in combination with moderate inhibitors of CYP3A4, with strong or moderate inhibitors of CYP2D6, in patients known to be CYP2D6 poor metabolizers, or in combination with other cytochrome P450 inhibitors. (टैम्सुलोसिन लेबल, चेतावनियां और सावधानियां)

Digoxin and Theophylline Dosage adjustments are not necessary when a tamsulosin hydrochloride capsule is administered concomitantly with digoxin or theophylline [see Clinical Pharmacology ( 12.3 )] . (टैम्सुलोसिन लेबल, दवाओं के इंटरैक्शन)

Digoxin and Theophylline Dosage adjustments are not necessary when a tamsulosin hydrochloride capsule is administered concomitantly with digoxin or theophylline [see Clinical Pharmacology ( 12.3 )] . (टैम्सुलोसिन लेबल, दवाओं के इंटरैक्शन)

Digoxin and Theophylline Dosage adjustments are not necessary when a tamsulosin hydrochloride capsule is administered concomitantly with digoxin or theophylline [see Clinical Pharmacology ( 12.3 )] . (टैम्सुलोसिन लेबल, दवाओं के इंटरैक्शन)

Digoxin and Theophylline Dosage adjustments are not necessary when a tamsulosin hydrochloride capsule is administered concomitantly with digoxin or theophylline [see Clinical Pharmacology ( 12.3 )] . (टैम्सुलोसिन लेबल, दवाओं के इंटरैक्शन)

Use with caution in combination with moderate inhibitors of CYP3A4, with strong or moderate inhibitors of CYP2D6, in patients known to be CYP2D6 poor metabolizers, or in combination with other cytochrome P450 inhibitors. (टैम्सुलोसिन लेबल, चेतावनियां और सावधानियां)

Use with caution in combination with moderate inhibitors of CYP3A4, with strong or moderate inhibitors of CYP2D6, in patients known to be CYP2D6 poor metabolizers, or in combination with other cytochrome P450 inhibitors. (टैम्सुलोसिन लेबल, चेतावनियां और सावधानियां)

• Exercise caution with concomitant administration of warfarin ( 5.2 , 7.4 , 12.3 ) (टैम्सुलोसिन लेबल, चेतावनियां और सावधानियां)

Caution is advised when alpha adrenergic blocking agents including tamsulosin hydrochloride are coadministered with PDE5 inhibitors. (टैम्सुलोसिन लेबल, चेतावनियां और सावधानियां)

Use with caution in combination with moderate inhibitors of CYP3A4, with strong or moderate inhibitors of CYP2D6, in patients known to be CYP2D6 poor metabolizers, or in combination with other cytochrome P450 inhibitors. (टैम्सुलोसिन लेबल, चेतावनियां और सावधानियां)

Caution is advised when alpha adrenergic blocking agents including tamsulosin hydrochloride are coadministered with PDE5 inhibitors. (टैम्सुलोसिन लेबल, चेतावनियां और सावधानियां)

Alpha-adrenergic blockers and PDE5 inhibitors are both vasodilators that can lower blood pressure. (टैम्सुलोसिन लेबल, चेतावनियां और सावधानियां)

Alpha-adrenergic blockers and PDE5 inhibitors are both vasodilators that can lower blood pressure. (टैम्सुलोसिन लेबल, चेतावनियां और सावधानियां)

Alpha-adrenergic blockers and PDE5 inhibitors are both vasodilators that can lower blood pressure. (टैम्सुलोसिन लेबल, चेतावनियां और सावधानियां)

• Drugs that counter the pressor effects of epinephrine include alpha blockers, vasodilators such as nitrates, diuretics, antihypertensives, and ergot alkaloids. (एड्रेनालिन लेबल, दवाओं के इंटरैक्शन)

Alpha-adrenergic blockers and PDE5 inhibitors are both vasodilators that can lower blood pressure. (टैम्सुलोसिन लेबल, चेतावनियां और सावधानियां)

Alpha-adrenergic blockers and PDE5 inhibitors are both vasodilators that can lower blood pressure. (टैम्सुलोसिन लेबल, चेतावनियां और सावधानियां)

Use in Patients with Pheochromocytoma If BREVIBLOC injection is used in the setting of pheochromocytoma, give it in combination with an alpha-blocker, and only after the alpha-blocker has been initiated. (एस्मोलोल लेबल, चेतावनियां और सावधानियां)

Alpha-adrenergic blockers and PDE5 inhibitors are both vasodilators that can lower blood pressure. (टैम्सुलोसिन लेबल, चेतावनियां और सावधानियां)

Coadministration of dutasteride and tamsulosin resulted in similar changes to serum PSA as dutasteride monotherapy. (ड्यूटास्टेराइड लेबल, चेतावनियां और सावधानियां)

Alpha-adrenergic blockers and PDE5 inhibitors are both vasodilators that can lower blood pressure. (टैम्सुलोसिन लेबल, चेतावनियां और सावधानियां)

Alpha-adrenergic blockers and PDE5 inhibitors are both vasodilators that can lower blood pressure. (टैम्सुलोसिन लेबल, चेतावनियां और सावधानियां)

Alpha-adrenergic blockers and PDE5 inhibitors are both vasodilators that can lower blood pressure. (टैम्सुलोसिन लेबल, चेतावनियां और सावधानियां)

Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of midodrine hydrochloride. (मिडोड्रिन लेबल, दवाओं के इंटरैक्शन)

Alpha-adrenergic blockers and PDE5 inhibitors are both vasodilators that can lower blood pressure. (टैम्सुलोसिन लेबल, चेतावनियां और सावधानियां)

Pheochromocytoma: Initiate therapy with an alpha blocker. (मेटोप्रोलोल लेबल, चेतावनियां और सावधानियां)

Pheochromocytoma: First initiate therapy with an alpha blocker. (मेटोप्रोलोल और हाइड्रोक्लोरोथायज़ाइड लेबल, चेतावनियां और सावधानियां)

Alpha-adrenergic blockers and PDE5 inhibitors are both vasodilators that can lower blood pressure. (टैम्सुलोसिन लेबल, चेतावनियां और सावधानियां)

Alpha-adrenergic blockers and PDE5 inhibitors are both vasodilators that can lower blood pressure. (टैम्सुलोसिन लेबल, चेतावनियां और सावधानियां)

Alpha-adrenergic blockers and PDE5 inhibitors are both vasodilators that can lower blood pressure. (टैम्सुलोसिन लेबल, चेतावनियां और सावधानियां)